Silo Pharma (NASDAQ:SILO – Get Free Report) posted its earnings results on Friday. The company reported ($0.21) EPS for the quarter, topping the consensus estimate of ($4.80) by $4.59, Zacks reports. Silo Pharma had a negative net margin of 6,726.39% and a negative return on equity of 81.75%.
Silo Pharma Stock Performance
NASDAQ SILO traded down $0.07 during trading on Friday, hitting $1.84. 48,855 shares of the company’s stock traded hands, compared to its average volume of 39,794. The stock has a market capitalization of $2.93 million, a price-to-earnings ratio of -0.42 and a beta of 0.81. Silo Pharma has a 12-month low of $1.10 and a 12-month high of $10.43. The business has a 50 day moving average of $1.56 and a 200-day moving average of $4.35.
Wall Street Analysts Forecast Growth
Separately, Weiss Ratings downgraded shares of Silo Pharma from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, August 21st. One equities research analyst has rated the stock with a Sell rating. According to MarketBeat, the stock presently has an average rating of “Sell”.
Check Out Our Latest Report on Silo Pharma
About Silo Pharma
Silo Pharma, Inc. is a development-stage biopharmaceutical company focused on developing therapeutics that combine traditional pharmaceutical approaches with psychedelic research. The company’s programs are intended to address conditions involving pain, inflammation, neurological disorders, and mental health. Silo Pharma’s pipeline has included SP-26, an investigational ketamine-based implant designed to provide sustained drug delivery and being explored for conditions such as fibromyalgia. Its research portfolio has also included intranasal formulations and other therapeutics targeting disorders such as post-traumatic stress disorder and Alzheimer’s disease.
Read More
- Five stocks we like better than Silo Pharma
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Silo Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silo Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
